U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

A surprise executive order could delay drug price cuts and supercharge profits for the industry's biggest players ...

The Trump administration made a decidedly pro-industry statement on the Inflation Reduction Act (IRA). In an executive order issued Tuesday, President Donald Trump outlined changes to the Biden ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

President Donald Trump’s executive order paved the way for Medicare to negotiate drug prices and brought real reform to the ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products that should not be used, sold or distributed.

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...